Open label pilot of personalized, neuroimaging-guided theta burst stimulation in early-stage Alzheimer's disease.

ABSTRACT:

Background

Alzheimer's disease (AD) is characterized by cerebral amyloid plaques and neurofibrillary tangles and disruption of large-scale brain networks (LSBNs). Transcranial magnetic stimulation (TMS) has emerged as a potential non-invasive AD treatment that may serve as an adjunct therapy with FDA approved medications.

Methods

We conducted a 10-subject open label, single site study evaluating the effect of functional connectivity-resting state functional MRI guided-approach to TMS targeting with dysfunctional LSBNs in subjects with biomarker-confirmed early-stage AD (https://clinicaltrials.gov/study/NCT05292222). Subjects underwent pre-post imaging and testing to assess connectivity dysfunction and cognition. All participants received intermittent theta burst stimulation

SUBMITTER: Kashyap B 

PROVIDER: S-EPMC11663868 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature